Welcome back! Today, we are looking at Modafinil and it's nuanced use in psychiatry.

References:

1. Provigil (modafinil) [prescribing information]. North Wales, PA: Teva Pharmaceuticals USA, Inc. U.S. Food and Drug Administration. Available at: https://www.accessdata.fda.gov/drugsatfdadocs/label/2015/020717s037s038lbl.pdf

2. Schwartz JR. Modafinil in the treatment of excessive sleepiness. Drug Des Devel Ther. 2009;2:71–85.

3. Kaplan S, Goehring EL Jr, Engel T, et al. Cardiovascular outcomes associated with modafinil in patients with obstructive sleep apnea. Pharmacoepidemiol Drug Saf. 2018;27(11):1182–1190. doi:10.1002/pds.4642

4. Cortese S, Adamo N, Del Giovane C, et al. Comparative efficacy and tolerability of medications for attention-deficit hyperactivity disorder in children, adolescents, and adults: a systematic review and network meta-analysis. Lancet Psychiatry. 2018;5(9):727–738. doi:10.1016/S2215-0366(18)30269-4

5. Goss AJ, Kaser M, Costafreda SG, Sahakian BJ, Fu CH. Modafinil augmentation therapy in unipolar and bipolar depression: a systematic review and meta-analysis of randomized controlled trials. J Clin Psychiatry. 2013;74(11):1101–1107. doi:10.4088/JCP.13r08560

6. Bahji A, Mesbah-Oskui L. Comparative efficacy and safety of stimulant-type medications for depression: a systematic review and network meta-analysis. J Affect Disord. 2021;292:416–423. doi:10.1016/j.jad.2021.05.119

7. Nunez NA, Singh B, Jorgensen A, et al. Efficacy and tolerability of adjunctive modafinil/armodafinil in bipolar depression: a meta-analysis of randomized controlled trials. Bipolar Disord. 2020;22(2):109–120. doi:10.1111/bdi.12859

Welcome Back! Today we are discussing the medication Naltrexone and its uses in psychiatry.

References:

• https://www.ncbi.nlm.nih.gov/books/NBK534811/

• https://pubmed.ncbi.nlm.nih.gov/24825644/

• https://pubmed.ncbi.nlm.nih.gov/26798982/

• https://www.nejm.org/doi/full/10.1056/NEJMct0801733

• https://pubmed.ncbi.nlm.nih.gov/26798982/

Welcome back! Today, we will be discussing the placebo effect.

References:

https://pubmed.ncbi.nlm.nih.gov/16503356/

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6003660/

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8556377/

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3714297/

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6694178/

https://www.psychiatrypodcast.com/psychiatry-psychotherapy-podcast/2018/11/19/understanding-placebo

Welcome back! Today we are talking all about Amantadine, and it's uses in psychiatry.

Welcome back! Today we are featuring the two FDA-approved medications for tardive dyskinesia, the VMAT2 inhibitors Valbenazine (Ingrezza) and Deutetrabenazine (Austedo).

References:

https://pubmed.ncbi.nlm.nih.gov/41626799/

https://www.ncbi.nlm.nih.gov/books/NBK548187/

https://pubmed.ncbi.nlm.nih.gov/41626799/

We are back with another special guest episode! Please welcome Dr. Allen Frances, who was intricately involved in the formation of both the DSM III and DSM IV, the latter of which he served as chair.

https://x.com/AllenFrancesMD

https://www.amazon.com/stores/author/B001HO76FU

https://www.psychiatrictimes.com/authors/allen-frances-md

Welcome back! Today we will be doing a brief episode on Topiramate [Topamax], and its clinical uses in psychiatry.

References:

• https://pubmed.ncbi.nlm.nih.gov/21438989/

• https://pubmed.ncbi.nlm.nih.gov/18774432/

• https://pubmed.ncbi.nlm.nih.gov/25899459/

• https://pmc.ncbi.nlm.nih.gov/articles/PMC1088011/

• https://pmc.ncbi.nlm.nih.gov/articles/PMC2671954/

• https://pubmed.ncbi.nlm.nih.gov/38706338/

• https://pubmed.ncbi.nlm.nih.gov/20207521/

Welcome back, today we are discussing a deceptively difficult topic: What makes something a psychiatric illness? We are joined by our guest Dr. Mark Ruffalo. He is a psychotherapist in private practice in Tampa, FL, and who also serves as Assistant Professor of Psychiatry at the University of Central Florida College of Medicine as well an Adjunct Assistant Professor of Psychiatry at Tufts University School of Medicine. 

Dr. Ruffalo's Website: https://www.drruffalo.com/

Dr. Ruffalo's LinkedIn: https://www.linkedin.com/in/mark-l-ruffalo-71929063

PRISM: https://www.psychiatrictimes.com/view/use-of-the-prism-diagnostic-instrument-in-clinical-practice

PRISM Writing Contest: https://www.psychiatrictimes.com/view/prism-writing-contest-more-on-this-new-diagnostic-tool-from-mark-ruffalo-msw-dpsa

Welcome back! Today we are at the highly prescribed and popular benzodiazepine Lorazepam, also known as Ativan. We look at its uses in psychiatry, especially catatonia. But despite anecdotal efficacy, does the evidence hold up?

References:

• https://www.ncbi.nlm.nih.gov/books/NBK532890/

• https://pubmed.ncbi.nlm.nih.gov/36805317/

• https://pubmed.ncbi.nlm.nih.gov/6120058/

• https://pubmed.ncbi.nlm.nih.gov/10229064/

• https://psychopharmacologyinstitute.com/section/catatonia-diagnosis-the-lorazepam-challenge-2911-5899/

Welcome back! Today we are embarking into the first of hopefully several episodes on the importance of vitamins and minerals in mental health. We will specifically be looking at the role of iron deficiency in psychiatry and do an overview on some of the recent research that's been published.

References:

• https://www.ncbi.nlm.nih.gov/books/NBK557376/

• https://www.sciencedirect.com/science/article/pii/S0268960X25000827#bb0165

• https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2823909

• https://www.sciencedirect.com/science/article/pii/S1389945717315599

• https://pubmed.ncbi.nlm.nih.gov/40841680/

• https://pubmed.ncbi.nlm.nih.gov/1677067/

• https://www.thelancet.com/journals/eclinm/article/PIIS2589-5370(23)00463-7/fulltext

• https://pmc.ncbi.nlm.nih.gov/articles/PMC6139360/